182,850 Shares in Johnson & Johnson $JNJ Purchased by Border to Coast Pensions Partnership Ltd

Border to Coast Pensions Partnership Ltd acquired a new position in Johnson & Johnson (NYSE:JNJ) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 182,850 shares of the company’s stock, valued at approximately $44,833,000.

Several other large investors have also bought and sold shares of the company. Greenberg Financial Group purchased a new stake in Johnson & Johnson in the fourth quarter worth about $954,000. World Investment Advisors lifted its holdings in shares of Johnson & Johnson by 19.6% during the fourth quarter. World Investment Advisors now owns 161,343 shares of the company’s stock valued at $33,390,000 after purchasing an additional 26,450 shares during the last quarter. JT Stratford LLC lifted its holdings in shares of Johnson & Johnson by 7.6% during the third quarter. JT Stratford LLC now owns 59,577 shares of the company’s stock valued at $11,047,000 after purchasing an additional 4,216 shares during the last quarter. Coldstream Capital Management Inc. boosted its position in shares of Johnson & Johnson by 9.8% in the 3rd quarter. Coldstream Capital Management Inc. now owns 95,662 shares of the company’s stock worth $17,738,000 after purchasing an additional 8,533 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its position in shares of Johnson & Johnson by 9.0% in the 3rd quarter. Victory Capital Management Inc. now owns 4,594,658 shares of the company’s stock worth $851,941,000 after purchasing an additional 377,743 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received a positive CHMP opinion for expanded use of its multiple myeloma drug Tecvayli in combination with Darzalex SC, which could broaden the treatment’s commercial opportunity if approved. Article Title
• Positive Sentiment: JNJ hit a new 52-week high as biotech shares rallied, with investors favoring large-cap healthcare names that have visible pipelines, approvals, and deal-related momentum. Article Title
• Positive Sentiment: Analysts highlighted JNJ’s recent share strength and noted that upward earnings estimate revisions could support additional near-term gains. Article Title
• Positive Sentiment: Johnson & Johnson won another talc-related lawsuit, with a Los Angeles jury finding the company was not negligent in a case involving ovarian cancer claims. Article Title
• Positive Sentiment: Guggenheim raised its price target on JNJ to $270 and reiterated a Buy rating, reflecting continued confidence ahead of the company’s upcoming earnings season. Article Title
• Neutral Sentiment: Commentary about JNJ’s dividend appeal and healthcare sector strength reinforces its status as a stable income stock, but does not add a new fundamental catalyst on its own. Article Title

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $258.24 on Tuesday. The stock has a market cap of $621.65 billion, a P/E ratio of 29.85, a P/E/G ratio of 2.49 and a beta of 0.26. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The stock’s fifty day moving average is $231.39 and its 200 day moving average is $230.03. Johnson & Johnson has a one year low of $151.52 and a one year high of $258.58.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.Johnson & Johnson’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were paid a dividend of $1.34 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date was Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is presently 61.97%.

Analysts Set New Price Targets

JNJ has been the subject of a number of analyst reports. Wells Fargo & Company raised their price objective on Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a research report on Wednesday, April 15th. Weiss Ratings downgraded Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday, June 15th. HSBC increased their target price on Johnson & Johnson from $265.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Johnson Rice set a $270.00 price target on Johnson & Johnson in a research report on Friday. Finally, JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.70.

Insider Transactions at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.